Hasija Amit 4

What Happened

• Amit Hasija, Milestone Pharmaceuticals’ Chief Financial Officer and EVP of Corporate Development, had a 100,000-share performance stock unit (PSU) award vest on Dec 12, 2025 (converted to common shares) and subsequently sold shares via sell-to-cover to satisfy tax withholding. Reported sales: 58,007 shares on Dec 15, 2025 at a weighted average $2.32 ($134,576) and 12,245 shares on Jan 26, 2026 at $1.93 ($23,633). The filing also shows a conversion/exercise of 20,100 derivative shares on Jan 26, 2026 (acquired).

Key Details

• Transactions reported in Form 4 filed Jan 28, 2026, covering activity from Dec 12, 2025 through Jan 26, 2026.
• Dec 12, 2025: PSU award of 100,000 shares became vested/convertible (reported as award/derivative; acquisition price $0.00 for derivative).
• Dec 15, 2025: Sold 58,007 shares at a weighted avg price $2.32 — proceeds ~$134,576 (F4: multiple prices aggregated).
• Jan 26, 2026: Converted/exercised 20,100 derivative shares (M) and sold 12,245 shares at $1.93 — proceeds ~$23,633.
• Total shares sold (reported here): 70,252 for total cash proceeds of about $158,209.
• Shares owned after these transactions: not specified in the provided extract.
• Notable footnotes:
  • F1–F2: The 100,000 award was a PSU that vested upon FDA approval of Cardamyst (etripamil); each PSU equals one common share.
  • F3: The sales were sell-to-cover transactions to satisfy income tax withholding from PSU/RSU vesting.
  • F7: Certain RSUs vest in equal annual installments starting Jan 26, 2026 (illustrates ongoing vesting schedule).
  • F4: Dec 15 sale price is a weighted average; the filer can provide breakdown on request.

Context

• These transactions appear routine: PSUs vested (a non-cash award converted to shares) and the insider sold a portion to cover tax obligations. That is different from an open-market purchase, which some investors view as a stronger bullish signal.
• The Form 4 reports conversion/exercise of derivative awards and subsequent sell-to-cover sales; this is common when equity awards vest. The filing does not, by itself, explain any change in company outlook or insider sentiment.